238 related articles for article (PubMed ID: 14615378)
1. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.
Lee JW; Chung HY; Ehrlich LA; Jelinek DF; Callander NS; Roodman GD; Choi SJ
Blood; 2004 Mar; 103(6):2308-15. PubMed ID: 14615378
[TBL] [Abstract][Full Text] [Related]
2. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.
Choi SJ; Oba T; Callander NS; Jelinek DF; Roodman GD
Blood; 2003 May; 101(10):3778-83. PubMed ID: 12560229
[TBL] [Abstract][Full Text] [Related]
3. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.
Han JH; Choi SJ; Kurihara N; Koide M; Oba Y; Roodman GD
Blood; 2001 Jun; 97(11):3349-53. PubMed ID: 11369623
[TBL] [Abstract][Full Text] [Related]
4. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
5. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
6. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
Terpos E; Politou M; Viniou N; Rahemtulla A
Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
[TBL] [Abstract][Full Text] [Related]
7. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
8. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
9. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
10. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.
Choi SJ; Cruz JC; Craig F; Chung H; Devlin RD; Roodman GD; Alsina M
Blood; 2000 Jul; 96(2):671-5. PubMed ID: 10887133
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
12. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
13. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival.
Okamatsu Y; Kim D; Battaglino R; Sasaki H; Späte U; Stashenko P
J Immunol; 2004 Aug; 173(3):2084-90. PubMed ID: 15265944
[TBL] [Abstract][Full Text] [Related]
14. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
[TBL] [Abstract][Full Text] [Related]
15. [Bone disease in multiple myeloma and its mechanism].
Abe M
Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation.
Lai FP; Cole-Sinclair M; Cheng WJ; Quinn JM; Gillespie MT; Sentry JW; Schneider HG
Br J Haematol; 2004 Jul; 126(2):192-201. PubMed ID: 15238139
[TBL] [Abstract][Full Text] [Related]
17. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
[TBL] [Abstract][Full Text] [Related]
18. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
19. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL.
Watanabe T; Kukita T; Kukita A; Wada N; Toh K; Nagata K; Nomiyama H; Iijima T
J Endocrinol; 2004 Jan; 180(1):193-201. PubMed ID: 14709158
[TBL] [Abstract][Full Text] [Related]
20. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
